Aptus, LLC, an Upstate-based cardiovascular bioreactor company, received a University Start-up Assistance Program (USAP) award.
The amount of the funding was not disclosed.
The company intends to use the funds to accelerate its tissue-engineering and regenerative-medicine efforts.
Based on research from Clemson University, Aptus’ cardiovascular bioreactors and custom-designed solutions provide mechanical conditioning of printed organs, development of recellularized scaffolds and physiological testing of devices. These bioreactor systems will enable the company to continue developing the next generation of tissue-engineered heart valve replacements.